New hope for tough breast cancer: Final-Stage trial tests promising drug
NCT ID NCT05347134
Summary
This study is testing an investigational drug called SKB264 for people with advanced triple-negative breast cancer that has spread or returned and has not responded to at least two prior standard treatments. The goal is to see if SKB264 works better than other chemotherapy options chosen by doctors to slow cancer growth and help patients live longer. It is a large, late-stage trial for adults aged 18 to 75 who have already been treated with taxane chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, 100021, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.